- CEO
- Chandrakant V. Gogri
- Full Time Employees
- 2,831
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- Mahendra Industrial Estate Mumbai MA India 400 022
- IPO Date
- May 12, 1993
- Business
- Aarti Drugs Limited manufactures active pharmaceutical ingredients, pharmaceutical intermediates, specialty chemicals, and formulations through its wholly-owned subsidiary Pinnacle Life Science Private Limited. The company produces APIs such as ciprofloxacin hydrochloride, metronidazole, metformin HCl, ketoconazole, and ofloxacin; pharmaceutical intermediates including fluoroquinolones and nitroimidazoles; and specialty chemicals such as salicylic acid, trimethylamine, dimethylamine, monomethylamine, benzene sulphonyl chloride, and methyl nicotinate. Founded in 1984 and headquartered in Mumbai, India, as part of the Aarti Group of Industries, Aarti Drugs operates 13 manufacturing facilities, primarily in Maharashtra including Tarapur and Sayakha, serving over 100 countries with approximately 50 API molecules and 80 finished products targeted at generic pharmaceutical sectors.
The company pursues backward integration and capacity expansions, including the commissioning of its Sayakha amines plant in September 2025 to enhance raw material security for metformin production and scaling Tarapur salicylic acid output to 500 tonnes monthly by Q4 FY26. Aarti Drugs completed a share buyback of 6.65 lakh equity shares at Rs 900 each in September 2025, reducing paid-up capital to Rs 91.27 crore, and plans Rs 150-200 crore capex in FY26 for new product introductions and facility upgrades amid a focus on US and EU regulatory approvals for high-value API exports. These initiatives support double-digit revenue growth, as evidenced by Q2 FY26 results showing 9% year-over-year revenue increase to Rs 653 crore and 23% EBITDA rise to Rs 84 crore.